Aequus Pharmaceuticals (CVE:AQS) Shares Down 28.6%

Aequus Pharmaceuticals Inc. (CVE:AQS) traded down 28.6% during trading on Friday . The stock traded as low as C$0.03 and last traded at C$0.03. Approximately 321,428 shares changed hands during trading, an increase of 60% from the average session volume of 201,068 shares. The stock had previously closed at C$0.04.

Aequus Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.09. The stock’s fifty day moving average price is C$0.02 and its 200-day moving average price is C$0.02. The firm has a market cap of C$3.98 million, a PE ratio of -1.25 and a beta of 0.17.

Aequus Pharmaceuticals (CVE:AQS) last issued its earnings results on Monday, April 29th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.05 million for the quarter. As a group, equities analysts forecast that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current fiscal year.

Aequus Pharmaceuticals Company Profile

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.